顾忠泽介绍，器官芯片技术是在微流控芯片上构建一个微型仿生系统，如同为细胞搭建一个"智慧房 屋"。微流控是在微米尺度的通道中精确控制微量流体的技术。因此，这样的"智慧房屋"能提供营养， 更能精密控制微环境，实时监测在其中生长的类器官的"生命体征"。 科研人员利用微型仿生系统，能在人体外高效、精准地模拟人体器官对药物或外界刺激的反应。团队发 现，在检测药物肝毒性方面，器官芯片达到90%及以上准确率，而传统动物实验的准确率通常在50%— 60%。 □ 本报记者 谢诗涵 徐冠英 近日，美国环境保护署（EPA）宣布，加速实现"到2035年终止所有由EPA开展或资助的哺乳动物实 验"的政策目标，推动毒理学评估从依赖动物模型转向基于人类细胞、器官芯片、人工智能和高通量体 外测试的新方法学。 随着"非动物实验浪潮"来袭，器官芯片技术日益受到关注。目前，国内器官芯片领域的研究团队尚属少 数。其中，东南大学器官芯片研究院院长、数字医学工程全国重点实验室主任顾忠泽团队"十年磨一 剑"，成功推动成果产业化，是该领域极具代表性的团队。近日，记者走进这支团队及其孵化的江苏艾 玮得生物科技有限公司，探秘器官芯片究竟如何运作、有什么作用、已 ...

Core Insights - The innovative drug HRS-1893 has achieved a significant breakthrough with a licensing agreement between Heng Rui Medicine and Braveheart Bio, with a potential total transaction value of nearly 8 billion RMB [1][5] - The collaboration highlights the international recognition of China's innovative drug research and the focus on Southeast University's organ-on-a-chip technology [1][5] Group 1: Drug Development and Mechanism - HRS-1893 is designed to treat obstructive hypertrophic cardiomyopathy and functions as a selective inhibitor of cardiac myosin [3] - The drug's development involved collaboration with Professor Gu Zhongze's team at Southeast University, utilizing organ-on-a-chip technology for cell activity screening [3][7] Group 2: Clinical Trials and Licensing Agreement - HRS-1893 received approval for clinical trials in May 2023, marking it as the first new drug in China to use organ-on-a-chip data for such approval [5] - Braveheart Bio will have exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding certain regions in China, with Heng Rui Medicine set to receive an upfront payment of $7.5 million and potential milestone payments totaling up to $1.013 billion [5][8] Group 3: Technological Advancements and Future Plans - The organ-on-a-chip team at Southeast University has made significant advancements in key technologies over the past decade, achieving breakthroughs in high-precision 3D printing and functional biomaterials [7] - Future plans include further technological innovation and collaboration with more pharmaceutical companies to create new pathways for drug development and precision medicine [8]

Core Concept - The emergence of organ-on-a-chip technology represents a significant advancement in biomedical research, offering a more accurate and ethical alternative to traditional animal testing methods [4][7]. Industry Overview - Organ chips are micro-engineered devices that simulate human organ functions using human cells, providing a platform for drug testing and disease modeling [2][3]. - The global organ-on-a-chip market is projected to grow at a compound annual growth rate (CAGR) of 31.2% from 2024 to 2030, indicating strong market potential [8]. Technological Advancements - Organ chips utilize microfluidic technology to create a controlled environment for cell growth, mimicking the physiological conditions of human organs [2][3]. - High-throughput organ chips can conduct thousands of tests simultaneously, significantly reducing the time and resources needed for drug development [5][6]. Advantages Over Traditional Methods - Organ chips can provide more accurate predictions of human responses to drugs compared to animal models, with studies showing accuracy improvements of 7 to 8 times in predicting drug-induced liver damage [4]. - The cost of using organ chips for drug testing is only 10% to 20% of that of traditional animal models, making it a cost-effective solution for pharmaceutical companies [7]. Applications in Drug Development - Organ chips can be used to test the efficacy and safety of drugs on patient-specific cells, allowing for personalized medicine approaches without risking patient health [7]. - The technology serves as a complementary tool to existing drug development processes, potentially shortening the research timeline and reducing costs [7].

Core Viewpoint - The development of organ-on-a-chip technology by Wuhan First Hospital significantly reduces the drug research and development cycle and experimental costs while improving the accuracy of experimental data [4][5][10]. Group 1: Organ-on-a-Chip Technology - The organ-on-a-chip technology can simulate various human organs, including blood vessels, skin, liver, intestines, and kidneys, allowing for preclinical research that replaces traditional cell models and animal testing [2][5]. - The multi-organ chip integrates multiple organ models and can simulate complex physiological and pathological processes, such as blood circulation, thereby enhancing the efficiency of drug development [5][9]. - The single-organ chip, such as the skin chip, can grow skin tissue with a layered structure from a small sample, providing a more accurate model for testing cosmetic products and drug efficacy [5][8]. Group 2: Applications in Drug Development - The organ-on-a-chip technology allows for real-time observation of cancer cell behavior and drug interactions, facilitating personalized treatment approaches, especially for cancer patients [9]. - The technology has been successfully used to create disease models for over 20 conditions, including atopic dermatitis and drug-induced liver injury, enhancing the understanding of disease mechanisms [9]. - The introduction of skin chips has improved the efficiency of testing cosmetic products, allowing for direct observation of collagen fiber growth and pigment deposition without relying on animal models [10].